Adipotide
Adipotide (FTPP) is supplied as a two-part homing/pro-apoptotic peptide construct for adipose-vasculature targeting research. Supplied strictly for laboratory and educational research. Not for human or veterinary use.
Vial amount
Purchase option
Checkout includes a research-use attestation. Materials are supplied only for laboratory and educational research.
Adipotide in research
Adipotide (FTPP) is supplied as a two-part homing/pro-apoptotic peptide construct for adipose-vasculature targeting research.
Metabolic signaling and receptor pathway research, framed for bench context only.
Bench context
Supplied as a research-grade reference material for documented laboratory and educational research workflows.
Available amounts
Select from the stocked vial amounts for Adipotide before adding the material to cart.
Claims discipline
No protocol instructions, no dosing, no medical advice, and no therapeutic or human-use promises.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, not for diagnostic or therapeutic use, not a drug or supplement.
As listed by the supplier in BioRegen's ordering system, shown here exactly as written for transparency. This is the vendor's own description, not independently verified, edited, or endorsed by BioRegen, and is not a BioRegen claim of any effect.
5mg
Disclaimer:
All products on this site are for Research and Development use only. Products are Not for Human Consumption of any kind. The statements made within this website have not been evaluated by the U.S. Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure, or prevent any disease.
Acein Adipotide represents a breakthrough in peptide research, focusing on the intricate dynamics of metabolic health and fat tissue. This advanced peptide is crafted to assist researchers in understanding how fat cells behave, offering insights into potential applications in weight management and metabolic studies. Research into Acein Adipotide has shown promising avenues for exploring how the body processes and stores fat, providing a foundation for future innovations. By targeting specific cellular structures, Acein Adipotide aids in the detailed examination of metabolic pathways. As scientific interest in peptides continues to grow, Acein Adipotide is positioned at the forefront, offering researchers a reliable and effective tool for their studies. This peptide is synthesized with meticulous attention to detail, ensuring high purity and potency, which are critical for accurate and reproducible research outcomes. Whether you are conducting laboratory experiments or theoretical research, Acein Adipotide delivers the precision and efficacy required for groundbreaking discoveries.
The full research picture, clearly labeled
BioRegen reports the entire research landscape for this compound across four clearly separated tiers, strongest evidence first. Lower tiers, including community and anecdotal reports, are labeled as such and are not BioRegen claims.
There is no established human efficacy evidence for Adipotide (FTPP). No completed controlled human trials demonstrating weight-loss or metabolic benefit have been reported in the published literature available to us, and human safety has not been established. Any human-effect statements about this compound should therefore be treated as unverified.
Adipotide is a peptidomimetic described by researchers as targeting the vasculature that supplies white adipose tissue, with the reported aim of inducing regression of fat-supporting blood vessels. The most frequently cited animal study, reported by Barnhart and colleagues in Science Translational Medicine (2011, doi:10.1126/scitranslmed.3002621), described weight loss and improved insulin resistance in obese rhesus monkeys. Investigators in that and related preclinical work also reported renal-toxicity signals, including effects on the kidneys, as a notable safety concern. All of these findings are preclinical (laboratory and animal) and have not been confirmed in humans.
Adipotide is occasionally discussed in biohacker and weight-management communities and in some mainstream media coverage that followed the 2011 monkey study, typically framing it as an experimental "fat-melting" candidate. Such discussion frequently omits the renal-toxicity concerns reported by researchers and overstates the maturity of the evidence. These accounts are unverified anecdotal commentary, not controlled data, and not a BioRegen claim.
Adipotide (FTPP) is not approved by the FDA or any comparable regulatory authority for any indication, and it remains an investigational research compound that has not advanced to established human use. BioRegen supplies it strictly for laboratory and educational research, not for human use.
Tiers are evidence categories, not endorsements. Clinical and preclinical entries summarize third-party published research. Community and anecdotal entries are unverified reports discussed by others, not findings and not BioRegen claims. Nothing here is medical advice, and no compound is approved for human or veterinary use except where explicitly stated under Regulatory status.
What the published research says about Adipotide
This section reports on published research referenced in BioRegen's own research library. It is not a claim by BioRegen that the compound provides any benefit, and nothing here is medical advice.
- Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W. Reversal of obesity by targeted ablation of adipose tissue. Nat Med. 2004. https://doi.org/10.1038/nm1048
- Staquicini FI, Cardo-Vila M, Kolonin MG, et al. Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. Proc Natl Acad Sci U S A. 2011. https://doi.org/10.1073/pnas.1114503108